Cardioprotective effects of zofenopril, a new angiotensin-converting enzyme inhibitor, on doxorubicin-induced cardiotoxicity in the rat

European Journal of Pharmacology

Volumn 414, Issue 1, 2001, Pages 71-78

  Sacco, Giuseppe ^a   Bigioni, Mario ^a   Evangelista, Stefano ^a   Goso, Cristina ^a   Manzini, Stefano ^a   Maggi, Carlo A ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

Angiotensin converting enzyme inhibitor; Anthracycline; Cardiotoxicity; Electrocardiography; Inotropic

Indexed keywords

ANTHRACYCLINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; ISOPRENALINE; ZOFENOPRIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARDIOTOXICITY; CHRONOTROPISM; CONTROLLED STUDY; DRUG EFFECT; ELECTROCARDIOGRAPHY; FEMALE; HEART FUNCTION; HEART HEMODYNAMICS; HEART INJURY; HEART PROTECTION; HEART WEIGHT; INOTROPISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; RAT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CAPTOPRIL; CARDIOTONIC AGENTS; DOXORUBICIN; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART; HEMODYNAMIC PROCESSES; ISOPROTERENOL; MALE; MICE; MICE, NUDE; ORGAN SIZE; OVARIAN NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0035936864     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(01)00782-8     Document Type: Article

References (56)

1. Captopril ameliorates myocardial and hematological toxicities induced by adriamycin
2. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction
3. Comparison of zofenopril and lisinopril to study the role of the sulphydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure
4. Early and delayed clinical cardiotoxicity of doxorubicin
5. Comparison of doxorubicin- and MEN 10755-induced long term progressive cardiotoxicity in the rat
6. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: Free radical and oxidant scavenging are sulphydryl dependent, but lipid peroxidation is inhibited by both sulphydryl- and nonsulphydryl-containing ACE inhibitors
7. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE)
8. Cardiac morphology and functional changes induced by epirubicin chemotherapy
9. Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme
10. Transgenic mice overexpressing metallothionein are not resistent to adriamycin cardiotoxicity
11. Cytoprotective agents for anthracyclines
12. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: Insight into its mechanism of action
13. Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Adjuvant Breast and Bowel Project experience
14. Involvment of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart
15. Protocols for screening chemical agents and natural products against animal tumors and other biological systems
16. G-nitro-L-arginine methyl ester-induced hypertension - Modulation of proinflammatory signals
17. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia
18. Doxorubicin cardiotoxicity in the rat: Comparison of electrocardiogram, transmembrane potential, and structural effects
19. Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy
20. Doxorubicin (adriamycin), a critical review of free radical dependent mechanism of citotoxicity
21. Cell-permeable superoxide dismutase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: Role of reactive oxygen and nitrogen intermediates
22. Alterations of intracellular calcium homeostasis and myocardial energetics in acute adriamycin-induced heart failure
23. A clinicopathologic analysis of adriamycin cardiotoxicity
24. Protective effects of captopril and enalapril on myocardial ischemia and reperfusion damage of rat
25. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats
26. Attenuation of myocardial reperfusion injury by sulphydryl-containing angiotensin converting enzyme inhibitors
27. An angiotensin-converting enzyme inhibitor protects against doxorubicin-induced impairment of calcium handling in neonatal rat cardiac myocytes
28. Protective effects of sulphydryl-containing enzyme inhibitors against free radical injury in endothelial cells
29. Adriamycin-induced cardiotoxicity (cardiomyopathy and congestive heart failure) in rats
30. Secondary alcohol metabolites mediate iron delocalization in cytosolic fractions of myocardial biopsies exposed to anticancer anthracyclines - Novel linkage between anthracycline metabolism and iron-induced cardiotoxicity
31. Equipotent antihypertensive agents variously affect pulsatile hemodynamics and regression of cardiac hypertrophy in spontaneously hypertensive rats
32. Current status of epirubicin (Farmorubicin) in the treatment of solid tumors
33. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine
34. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits
35. Chronic cardiotoxicity of doxorubicin (adriamycin) in the rat: Morphological and biochemical investigations
36. Doxorubicin cardiotoxicity: Analysis of prevailing hypotheses
37. 2+ channel from rat cardiac sarcoplasmic reticulum: Possible receptor-mediated mechanism of doxorubicin cardiomyopathy
38. Etiology of sarcoplasmic reticulum calcium release channel lesions in doxorubicin-induced cardiomyopathy
39. Anthracyclines and the heart
40. Doxorubicin-induced cardiomyopathy
41. Preclinical profile of zofenopril: An angiotensin converting enzyme inhibitor with peculiar cardioprotective properties
42. Angiotensin converting enzyme inhibition in heart, kidney, and serum studied ex vivo after administration of zofenopril, captopril, and lisinopril
43. Prevention of doxorubicin (adriamycin)-induced cardiomyopathy by simultaneous administration of angiotensin-converting enzyme inhibitor assessed by acoustic densitometry
44. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy
45. Guidelines for the welfare of animals in experimental neoplasia
46. Usefulness of a free radical scavenger in preventing doxorubicin-induced heart failure in gods
47. Cardiac disease induced by chronic adriamycin administration in dogs and evaluation of vitamin E and selenium as cardioprotectants
48. Relationship between doxorubicin-induced ECG changes and myocardial alterations in rats
49. Risk factors for doxorubicin-induced congestive heart failure
50. Inhibition of doxorubicin toxicity in cultured neonatal mouse cardiomyocytes with elevated matallothionein levels
51. Effects of doxorubicin on excitation-contraction coupling in guinea pig ventricular myocardium
52. Induction of antioxidants by adriamycin in mouse heart
53. 2+ channel/ryanodine receptor: Modulation by endogenous effectors, drugs and disease states